2010-10-18
Probi to add approx. 5 million SEK in net sales through extended collaboration with Camox Pharmaceuticals
Probi has signed an additional agreement with Camox Pharmaceuticals, one of the fastest growing pharmaceutical companies in South Africa. The new agreement follows the one signed in March 2010 regarding Probi´s immune product. It gives Camox Pharmaceuticals rights to launch two new line extensions in South Africa based on Probi’s flagship strain Lp299v™. The new agreement is expected to add approx. 5 million SEK to Probi´s net sales during the first 12 months after launch and it will contribute to profits already in 2011. This is in addition to revenues and profit expected from the first agreement with Camox.
